摘要
目的 系统评价抗IL-5抗体治疗支气管哮喘（哮喘）患者的疗效及安全性.方法 根据特定中英文检索词检索PubMed、EMbase、Springer、Ovid、Cochrane Library、ClinicalTrials.gov和CNKI、万方数据库的所有相关临床随机对照研究（RCT）,检索时间截至2017年2月.同时检索纳入文献的参考文献,并逐个进行质量评价和资料提取.采用RevMan5.3软件进行统计学分析.结果 共纳入20篇文献,23个RCT,共计6406例患者.荟萃分析结果显示,抗IL-5抗体可明显降低哮喘急性加重的发生率[RR =0.66,95％ CI（0.59,0.73）],改善患者FEV1 [MD =0.10,95％ CI （0.07,0.13）]、FEV1占预计值％[MD =3.90,95％ CI（1.86,5.95）]和哮喘生命质量问卷（AQLQ）评分[MD=0.24,95％ CI（0.16,0.32）],且降低了不良事件的发生风险[OR =0.71,95％ CI（0.58,0.87）].结论 抗IL-5抗体可降低哮喘患者急性加重的发生率,并改善患者肺功能及生命质量,且具有较好的耐受性.
Objective To evaluate the efficacy and safety of anti-Interleukin-5 therapy in patients with asthma.Methods Data were collected from PubMed,E-Mbase,Springer,Ovid,Cochrane Library,ClinicalTrials.gov,CNKI and Wanfang database （-Feb 2017）.Bibliographies of the retrieved articles were checked and analyzed.Results Twenty publications involving a total of 6 406 patients were used in the analysis,including 23 randomly controlled trials （RCTs） which compared anti-interleukin 5 monoclonal antibody with placebo.Pooled analyses showed that anti-interleukin 5 monoclonal antibody significantly reduced exacerbation risk [RR =0.66,95 % CI（0.59,0.73）],increased FEV1 [MD =0.10,95 % CI（0.07,0.13）] and FEV1 % predicted [MD =3.90,95% CI（1.86,5.95）],and improved the scores on the Asthma Quality of Life Questionnaire （AQLQ） [MD =0.24,95 % CI（0.16,0.32）].Anti-interleukin 5 monoclonal antibody was also associated with significantly decreased risk of adverse events than placebo [OR =0.71,95% CI （0.58,0.87）].Conclusion Anti-interleukin 5 monoclonal antibody reduces the risk of exacerbations and improves quality of life in patients with asthma,and is tolerated well.
出处
《中华结核和呼吸杂志》
CAS
CSCD
北大核心
2017年第11期835-844,共10页
Chinese Journal of Tuberculosis and Respiratory Diseases
